Analysis of Neutralization Antibodies in Patients With Mild COVID-19 Infection After 100 Days Using Microneutralization Test
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Neutralizing antibodies play a critical role in blocking viral infections and in viral clearanceduring acute infection. The microneutralization assay and enzyme-linked immunosorbentassay (ELISA) targeting the receptor binding domain were performed for 30 patients withmild coronavirus disease (COVID)-19 infections. The elapsed number of days between samplecollection and diagnosis was 115 days, and real-time polymerase chain reaction (PCR) cyclethreshold (Ct) values at diagnosis were recorded. Clinical characteristics and Ct values werecompared between neutralization antibody-positive and -negative patients as measured bythe microneutralization assay. Neutralization antibody-positive patients (n = 9) were likelyto be older, have low Ct values, have more pneumonia during admission, and have a higheroptical density in ELISA than the neutralization antibody-negative patients (n = 21). Elderlypeople seemed to have a higher viral load causing more pneumonia and to produce moreneutralization antibodies. Neutralization antibodies persisted in only 30% of patients asdetected by microneutralization test after 100 days of diagnosis.
Abstract
Neutralizing antibodies play a critical role in blocking viral infections and in viral clearanceduring acute infection. The microneutralization assay and enzyme-linked immunosorbentassay (ELISA) targeting the receptor binding domain were performed for 30 patients withmild coronavirus disease (COVID)-19 infections. The elapsed number of days between samplecollection and diagnosis was 115 days, and real-time polymerase chain reaction (PCR) cyclethreshold (Ct) values at diagnosis were recorded. Clinical characteristics and Ct values werecompared between neutralization antibody-positive and -negative patients as measured bythe microneutralization assay. Neutralization antibody-positive patients (n = 9) were likelyto be older, have low Ct values, have more pneumonia during admission, and have a higheroptical density in ELISA than the neutralization antibody-negative patients (n = 21). Elderlypeople seemed to have a higher viral load causing more pneumonia and to produce moreneutralization antibodies. Neutralization antibodies persisted in only 30% of patients asdetected by microneutralization test after 100 days of diagnosis.
참고문헌 (15)
- Sood N, "Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los Angeles County, California, on April 10-11, 2020", JAMA, 323, pp.2425~2427 (2020)
- Duan K, "Effectiveness of convalescent plasma therapy in severe COVID-19 patients", Proc Natl Acad Sci, 117, pp.9490~9496 (2020)
- Espejo AP, "Review of current advances in serologic testing for COVID-19", Am J Clin Pathol, 154, pp.293~304 (2020)
- Siracusano G, "Humoral immune responses in COVID-19 patients : a window on the state of the art", Front Immunol, 11, pp.1049~ (2020)
- Wu F, "Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China", JAMA Intern Med, 180, pp.1356~1362 (2020)
- Rogers TF, "Isolation of potent SARSCoV-2 neutralizing antibodies and protection from disease in a small animal model", Science, 369, pp.956~963 (2020)
- Zost SJ, "Potently neutralizing and protective human antibodies against SARS-CoV-2", Nature, 584, pp.443~449 (2020)
- Amanat F, "An in vitro microneutralization assay for SARS-CoV-2 serology and drug screening", Curr Protoc Microbiol, 58, pp.e108~ (2020)
- Manenti A, "Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus microneutralization assay in human serum samples", J Med Virol, 92, pp.2096~2104 (2020)
- Lee WT, "Neutralizing antibody responses in COVID-19 convalescent sera", J Infect Dis, 223, pp.47~55 (2021)
- Amanat F, "A serological assay to detect SARS-CoV-2 seroconversion in humans", Nat Med, 26, pp.1033~1036 (2020)
- "National Early Warning Score (NEWS)"[URL]
- Wang X, "Neutralizing antibodies responses to SARSCoV-2 in COVID-19 inpatients and convalescent patients", Clin Infect Dis, 71, pp.2688~2694 (2020)
- Choe PG, "Antibody responses 8 months after asymptomatic or mild SARS-CoV-2 infection", Emerg Infect Dis, 27, pp.928~931 (2021)
- Kadkhoda K, "COVID-19: are neutralizing antibodies neutralizing enough?", Transfusion, 60, pp.1602~1603 (2020)